SMMT vs. ADMA

Last updated Apr 2, 2026

Compare and contrast key facts about Summit Therapeutics Inc. (SMMT) and ADMA Biologics, Inc. (ADMA).

Performance

SMMT vs. ADMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Summit Therapeutics Inc. (SMMT) and ADMA Biologics, Inc. (ADMA). The values are adjusted to include any dividend payments, if applicable.

SMMT vs. ADMA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SMMT Summit Therapeutics Inc.	8.18%	-1.99%	583.72%	-38.59%	57.99%	-42.77%	193.75%	39.13%	-89.62%	29.44%
ADMA ADMA Biologics, Inc.	-50.05%	6.36%	279.42%	16.49%	175.18%	-27.69%	-51.25%	67.36%	-25.55%	-37.30%

Fundamentals

EPS SMMT : -$1.24 ADMA : $0.60
Total Revenue (TTM) SMMT : $0.00 ADMA : $510.17M
Gross Profit (TTM) SMMT : -$15.04M ADMA : $292.77M
EBITDA (TTM) SMMT : -$921.46M ADMA : $195.35M

Returns By Period

In the year-to-date period, SMMT achieves a 8.18% return, which is significantly higher than ADMA's -50.05% return. Over the past 10 years, SMMT has outperformed ADMA with an annualized return of 10.52%, while ADMA has yielded a comparatively lower 0.79% annualized return.

SMMT

• 1D: -0.21%
• 1M: 16.86%
• YTD: 8.18%
• 6M: -7.66%
• 1Y: 0.64%
• 3Y*: 121.12%
• 5Y*: 25.24%
• 10Y*: 10.52%

ADMA

• 1D: 1.11%
• 1M: -45.05%
• YTD: -50.05%
• 6M: -39.47%
• 1Y: -53.09%
• 3Y*: 40.14%
• 5Y*: 37.85%
• 10Y*: 0.79%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SMMT vs. ADMA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SMMT

SMMT Risk / Return Rank: 43
SMMT Sharpe Ratio Rank: 40
SMMT Sortino Ratio Rank: 46
SMMT Omega Ratio Rank: 49
SMMT Calmar Ratio Rank: 39
SMMT Martin Ratio Rank: 39

ADMA

ADMA Risk / Return Rank: 7
ADMA Sharpe Ratio Rank: 5
ADMA Sortino Ratio Rank: 7
ADMA Omega Ratio Rank: 8
ADMA Calmar Ratio Rank: 11
ADMA Martin Ratio Rank: 3

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SMMT vs. ADMA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Summit Therapeutics Inc. (SMMT) and ADMA Biologics, Inc. (ADMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SMMT	ADMA	Difference
Sharpe ratio Return per unit of total volatility	0.01	-0.93	+0.93
Sortino ratio Return per unit of downside risk	0.69	-1.32	+2.00
Omega ratio Gain probability vs. loss probability	1.11	0.83	+0.27
Calmar ratio Return relative to maximum drawdown	-0.03	-0.82	+0.79
Martin ratio Return relative to average drawdown	-0.04	-1.80	+1.75
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SMMT vs. ADMA - Sharpe Ratio Comparison

The current SMMT Sharpe Ratio is 0.01, which is higher than the ADMA Sharpe Ratio of -0.93. The chart below compares the historical Sharpe Ratios of SMMT and ADMA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SMMT	ADMA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.01	-0.93	+0.93
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.14	0.63	-0.50
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.07	0.01	+0.06
Sharpe Ratio (All Time) Calculated using the full available price history	0.04	0.01	+0.03

Correlation

The correlation between SMMT and ADMA is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SMMT vs. ADMA - Dividend Comparison

Neither SMMT nor ADMA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

SMMT vs. ADMA - Drawdown Comparison

The maximum SMMT drawdown since its inception was -95.75%, roughly equal to the maximum ADMA drawdown of -91.28%. Use the drawdown chart below to compare losses from any high point for SMMT and ADMA.

Drawdown Indicators

	SMMT	ADMA	Difference
Max Drawdown Largest peak-to-trough decline	-95.75%	-91.28%	-4.47%
Max Drawdown (1Y) Largest decline over 1 year	-62.26%	-66.18%	+3.92%
Max Drawdown (5Y) Largest decline over 5 years	-91.96%	-66.18%	-25.78%
Max Drawdown (10Y) Largest decline over 10 years	-95.75%	-87.33%	-8.42%
Current Drawdown Current decline from peak	-48.45%	-62.83%	+14.38%
Average Drawdown Average peak-to-trough decline	-57.79%	-52.92%	-4.87%
Ulcer Index Depth and duration of drawdowns from previous peaks	44.34%	30.12%	+14.22%

Volatility

SMMT vs. ADMA - Volatility Comparison

The current volatility for Summit Therapeutics Inc. (SMMT) is 21.21%, while ADMA Biologics, Inc. (ADMA) has a volatility of 32.15%. This indicates that SMMT experiences smaller price fluctuations and is considered to be less risky than ADMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SMMT	ADMA	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.21%	32.15%	-10.94%
Volatility (6M) Calculated over the trailing 6-month period	43.86%	44.57%	-0.71%
Volatility (1Y) Calculated over the trailing 1-year period	93.41%	57.46%	+35.95%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	185.23%	59.98%	+125.25%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	145.07%	69.11%	+75.96%

Financials